EMEA-000753-PIP02-16

Key facts

Invented name
Obizur
Active substance
susoctocog alfa
Therapeutic area
Haematology-Hemostaseology
Decision number
EMEA-000753-PIP02-16
PIP number
EMEA-000753-PIP02-16
Pharmaceutical form(s)
Powder and solvent for solution for injection
Condition(s) / indication(s)
Treatment of congenital haemophilia A with antibodies (inhibitors) to human factor VIII
Route(s) of administration
Intravenous use
Contact for public enquiries
Baxalta Innovations GmbH

E-mail: medinfoEMEA@takeda.com
Tel. +80066838470

Decision type
P: decision agreeing on a investigation plan, with or without partial waiver(s) and or deferral(s)

Decision

Related content

How useful was this page?

Add your rating